Search
17 studies match these filters. Showing 1–17 of 17 studies
| Registration number | Study | Status | Phase | Enrolment | Sites / countries | Start year | Last updated | Actions |
|---|---|---|---|---|---|---|---|---|
| NCT07207408 | Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age This study will evaluate the immunogenicity, safety, and tolerability of rF1V-1018 vaccine ✓ Contact✗ Claimed Nearest site: El Dorado, Kansas, United States — 85 km away · 4 sites in total | Recruiting | Phase 2 | 148target | 4 / 1 | 2025 | Jun 18, 2026 | |
| NCT06693895 | A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age The purpose of this study is to assess how well-tolerated GSK's investigational varicella vaccine (VNS Vaccine) is, in comparison to an already approved varicella vaccine (VV) known as Varivax. The study will be conducted on healthy children aged 12 to 15 months, and who have neither contracted vari… ✓ Contact✗ Claimed Nearest site: El Dorado, Kansas, United States — 85 km away · 46 sites in total | Recruiting | Phase 3 | 750target | 46 / 8 | 2024 | May 29, 2026 | |
| NCT05336240 | PCOM2 - The Physician Communication Intervention, Version 2.0 Poor quality of primary care providers' vaccine recommendations lead to low adolescent human papillomavirus vaccination rates and hundreds of thousands of adolescents unnecessarily at risk for HPV-associated cancers and diseases. Though a previous provider communication intervention, called PCOM, wa… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 2 sites in total · contact listed | Recruiting | Not applicable | 120target | 2 / 1 | 2023 | Aug 26, 2024 | |
| NCT07282665 | A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older The purpose of the study is to learn about how effective, safe, and tolerable the Clostridioides difficile (C. difficile) vaccine is in decreasing the number of C. difficile infections (pCDI) in adults 65 years of age or older. The participants will receive either the C. difficile vaccine or placeb… ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 185 sites in total | Recruiting | Phase 3 | 32,500target | 185 / 4 | 2025 | Sep 9, 2026 | |
| NCT07629440 | A Study to Learn About How a New Pneumococcal Vaccine Works in Infants. The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and otitis media (ear infections) in infants when compared to the pneumoco… ✓ Contact✗ Claimed Nearest site: Derby, Kansas, United States — 54 km away · 124 sites in total | Recruiting | Phase 3 | 3,230target | 124 / 3 | 2026 | Sep 8, 2026 | |
| NCT07779408 | Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above. The study aims to evaluate an egg-based H5N8 influenza vaccine up to 3 dose levels (low, medium, and high dose) given with or without adjuvant to see if the adjuvant improves vaccine effectiveness. The study will enroll healthy adults aged 18 years and over. Participants will receive 2 injections i… ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 16 sites in total | Recruiting | Phase 1 / Phase 2 | 640target | 16 / 1 | 2026 | Sep 15, 2026 | |
| NCT06237452 | VE303 for Prevention of Recurrent Clostridioides Difficile Infection The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo. The objectives and endpoints are identical for Stage 1 (recurrent CDI) and… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 215 sites in total | Recruiting | Phase 3 | 852target | 215 / 24 | 2024 | Sep 14, 2026 | |
| NCT05655182 | A Study of BLB-201 RSV Vaccine in Infants and Children This Phase 1/2a trial is a randomized, placebo-controlled trial to evaluate the safety, tolerability and immunogenicity of two ascending doses (10\^6 PFU and 10\^7 PFU) of intranasal BLB-201 (a recombinant parainfluenza virus type 5) administered in infants (8-24 months of age) and children (18-59 m… ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 16 sites in total · contact listed | Recruiting | Phase 1 / Phase 2 | 137target | 16 / 1 | 2023 | Jul 29, 2026 | |
| NCT06847321 | Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease This study is to test LHP588 in persons who have mild to moderate Alzheimer's disease (AD) who have shown progressive mental decline in the last year and who have P. gingivalis (Pg) infection. P. gingivalis infection has been linked to the development of dementia. LHP588 is designed to target the P.… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 38 sites in total · contact listed | Recruiting | Phase 2 | 300target | 38 / 1 | 2025 | Sep 15, 2026 | |
| NCT07453069 | Effect of FB301 on Vaginal Bacterial Profile in Women With Asymptomatic Vaginal Dysbiosis Undergoing a Mock Frozen Embryo Transfer Cycle The goal of this clinical trial is to evaluate FB301 during a mock frozen embryo transfer (FET) cycle in pre-menopausal women aged 18 to 40 years with a prior failed FET and a defined vaginal bacterial imbalance (dysbiosis). The main question it aims to answer is: • Does treatment with FB301 durin… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 4 sites in total · contact listed | Recruiting | Phase 2 | 30target | 4 / 1 | 2026 | Sep 3, 2026 | |
| NCT05491525 | Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 38 sites in total · contact listed | Recruiting | Phase 2 / Phase 3 | 71target | 38 / 16 | 2022 | Jun 15, 2026 | |
| NCT07466316 | A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) This phase III trial compares higher dose chemotherapy, with vincristine, dactinomycin and cyclophosphamide, over a shorter amount of time to lower dose chemotherapy plus maintenance, with vincristine, dactinomycin, cyclophosphamide, irinotecan and vinorelbine, over a longer amount of time, along wi… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 87 sites in total · contact listed | Recruiting | Phase 3 | 342target | 87 / 2 | 2026 | Aug 25, 2026 | |
| NCT06662786 | A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folini… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 239 sites in total | Recruiting | Phase 3 | 1,000target | 239 / 22 | 2024 | Aug 28, 2026 | |
| NCT06122077 | Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-care screening Low-Dose Computed Tomography (LDCT). ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 36 sites in total · contact listed | Recruiting | 20,000target | 36 / 1 | 2023 | Aug 5, 2025 | ||
| NCT06750094 | A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovor… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 251 sites in total | Recruiting | Phase 3 | 700target | 251 / 26 | 2024 | Aug 28, 2026 | |
| NCT03959085 | Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab ozogamicin is a monoclonal antibody, which is a type of protei… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 231 sites in total · contact listed | Recruiting | Phase 3 | 5,951target | 231 / 5 | 2019 | Aug 25, 2026 | |
| NCT03150693 | Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a chemotherapy dr… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 460 sites in total | Recruiting | Phase 3 | 303target | 460 / 2 | 2017 | Sep 2, 2026 |